股票代码： 600113 股票简称：浙江东日 公告编号：2025-037 浙江东日股份有限公司 第九届董事会第四十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对内容真实性、准确性和完整性承担法律责任。 浙江东日股份有限公司第九届董事会第四十二次会议，于 2025 年 7 月 4 日以传真、邮件或现场送达形式向全体董事发出通知，于 2025 年 7 月 9 日在公司 1 号会议室以现场结合通讯方式召开。会议 应出席董事 7 人，实际到会董事 7 人，分别是陈加泽、杨澄宇、赵陈 生、赵阿宝、费忠新、车磊、朱欣。公司高管人员列席会议。会议的 召集、召开及审议程序符合《公司法》、《公司章程》和《董事会议事 规则》的有关规定。会议由董事长陈加泽先生主持。 经审议，会议一致通过以下议案： 露的《关于董事会换届选举的公告》（公告编号：2025-038）。 一、审议通过《关于董事会换届选举暨提名第十届董事会非独立 董事候选人的议案》； 本议案在提交董事会前已经公司第九届董事会提名委员会 2025 年第一次会议审议通过，同意提交董事会审议。 鉴于公司第九届董事会成员任期 ...

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

浙江东日股份有限公司 关于非独立董事辞任暨选举第九届董事会职工董事的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对内容真实性、准确性和完整性承担法律责任。 一、非独立董事辞任情况 鉴于公司近期章程及组织架构已调整完成，为符合《上市公司章 程指引》《公司章程》关于董事会人员组成的相关规定，杨澄宇先生 基于个人意愿，申请辞去公司第九届董事会副董事长、董事职务，同 时一并辞去公司董事会战略委员会委员职务；叶郁郁先生基于个人意 愿，申请辞去公司第九届董事会董事职务，同时一并辞去公司董事会 战略委员会委员职务；黄胜凯先生基于个人意愿，申请辞去公司第九 届董事会董事职务，同时一并辞去公司董事会战略委员会委员职务； 郑哲峰先生基于个人意愿，申请辞去公司第九届董事会董事职务，同 时一并辞去公司董事会审计委员会委员职务。 股票代码： 600113 股票简称：浙江东日 公告编号：2025-035 根据《中华人民共和国公司法》《公司章程》等有关规定，杨澄 宇先生、叶郁郁先生、黄胜凯先生、郑哲峰先生辞去公司董事职务不 会导致公司董事会人数低于法定最低人数，不会影响公司董事会正常 运行， ...

股票代码： 600113 股票简称：浙江东日 公告编号：2025-036 浙江东日股份有限公司 第九届董事会第四十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对内容真实性、准确性和完整性承担法律责任。 浙江东日股份有限公司第九届董事会第四十一次会议，于 2025 年 7 月 2 日在公司 1 号会议室以现场结合通讯方式召开。会议应出席 董事 7 人，实际到会董事 7 人，分别是陈加泽、杨澄宇、赵陈生、赵 阿宝、费忠新、车磊、朱欣。公司高管人员列席会议。经全体董事一 致同意本次董事会豁免提前 5 日通知的时限要求。会议的召集、召开 及审议程序符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定。会议由董事长陈加泽先生主持。 经审议，会议一致通过以下议案： 一、审议通过《关于选举公司第九届董事会副董事长的议案》； 薪酬与考核委员会——召集人：费忠新；成员：车磊、朱欣。 提名委员会——召集人：朱欣；成员：车磊、赵陈生。 审计委员会——召集人：车磊；成员：费忠新、朱欣。 表决结果：赞成票 7 票，反对票 0 票，弃权票 0 票。 特此公告 浙江东日股份 ...

Group 1 - The A-share market showed a mixed pattern on July 2, with a total of 60 stocks hitting the daily limit up, and the overall success rate of limit-up stocks was 79% [1] - The focus of the market was on several strong-performing stocks, including Zhejiang Dongri in the brain-computer interface sector, which achieved its 7th limit-up in 12 days [1] - The marine economy sector performed notably well, with stocks like Shenwater Haina and Kelaite reaching their limit-up, while the aquaculture sector saw multiple stocks, including Guolian Aquatic and Zhangzidao, also hitting limit-up [1] Group 2 - The photovoltaic equipment sector received a net inflow of 4.491 billion yuan from main funds, ranking first among all industries [2] - Traditional industries such as steel, food and beverage, and energy metals also attracted significant attention from funds [2] - In contrast, the semiconductor sector faced a net outflow of 6.792 billion yuan from main funds, along with other tech sectors like communication equipment and software development experiencing outflow pressure [2]

Stock Performance - Several stocks related to deep-sea technology have shown significant gains, with Deepwater Haina leading at 20.00% increase, followed by other companies like Zhenhua Heavy Industry at 10.00% and Shenkai Co. at 10.01% [2][3][4] - In the photovoltaic sector, stocks such as Yao Pi Glass and Euro Crystal Technology have also performed well, with increases of 9.93% and 10.02% respectively [5][6] - The steel industry has seen a turnaround, with companies like Liugang Co. and Chongqing Steel achieving gains of 10.08% and 10.16% respectively [7][8] Industry Trends - The photovoltaic glass industry is experiencing a collective production cut of 30% starting from July, which is expected to reduce domestic glass output to approximately 45GW [4] - The nuclear power sector is gaining attention due to a significant agreement between Alphabet and a fusion energy company, marking a milestone in commercial power procurement [10] - The wind power sector is projected to grow rapidly, with offshore wind capacity expected to exceed 230GW globally by 2030, positioning China's deep-sea projects as key growth points [18] Emerging Opportunities - The innovative drug sector is supported by new measures from the National Healthcare Security Administration, which aims to include innovative drugs in basic medical insurance [16][17] - The sugar substitute market is expanding, with the approval of a new production company for allulose sugar, indicating potential growth in this niche [14][15] - The military industry is expected to see an increase in orders, reversing a downward trend, which could lead to positive growth in the second half of the year [20][21]

New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Core Viewpoint - Zhejiang Dongri, once a high-flying stock due to the "brain-computer interface" concept, saw its stock price plummet after clarifying that its main business is unrelated to this concept, leading to a significant market correction [1][2][4] Group 1: Stock Performance - From June 16 to June 27, Zhejiang Dongri's stock price surged for 10 consecutive trading days, with 6 days hitting the daily limit, resulting in a cumulative increase of 105.16% [2][3] - On June 30, the stock opened at 26.82 yuan, down 6.35%, and closed at the daily limit of 25.78 yuan, marking a decline of 9.99% [1] Group 2: Company Announcements - On June 27, Zhejiang Dongri issued a "Severe Abnormal Fluctuation Announcement," clarifying that its main business involves managing vegetable markets and selling tofu, with no connection to the "brain-computer interface" [1][2] - The company had previously issued multiple announcements, including a "Risk Warning Announcement," emphasizing that its daily operations do not involve the "brain-computer interface" business [3][4] Group 3: Market Manipulation Concerns - The stock's prior surge was characterized as speculative trading, with indications of potential market manipulation, especially given the company's clarifications about its business focus [2][3] - The misleading nature of the stock's rise based on the "brain-computer interface" concept has raised concerns about investor protection and the need for regulatory scrutiny [4]